During the past decade, Ustav hematologie a krevni transfuze conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 5 clinical trials were completed, i.e. on average, 62.5% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 3 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Ustav hematologie a krevni transfuze" #1 sponsor was "Celgene" with 4 trials, followed by "Agios Pharmaceuticals, Inc." with 1 trials sponsored, "Amgen" with 1 trials sponsored, "Hoffmann-La Roche" with 1 trials sponsored and "Janssen Research & Development, LLC" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ustav hematologie a krevni transfuze" #1 collaborator was "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "Chugai Pharmaceutical" with 1 trials as a collaborator and "Takeda Development Center Americas, Inc." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Ustav hematologie a krevni transfuze" are "Acute Myeloid Leukemia" (1 trials), "Anemia" (1 trials), "Blincyto Use in Routine Clinical Practice" (1 trials), "Cytomegalovirus (CMV)" (1 trials) and "Leukemia, Myeloid, Acute" (1 trials). Many other conditions were trialed in "Ustav hematologie a krevni transfuze" in a lesser frequency.

Most popular intervention types in "Ustav hematologie a krevni transfuze" are "Drug" (9 trials) and "Other" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Oral Azacitidine" (2 trials), "33A" (1 trials), "Best Supportiv Care (BSC)" (1 trials) and "Crovalimab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Ustav hematologie a krevni transfuze" are 11 trials for "All" genders.

Currently, there are NaN active trials in "Ustav hematologie a krevni transfuze". undefined are not yet recruiting, 3 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Ustav hematologie a krevni transfuze, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Ustav hematologie a krevni transfuze, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

Ustav hematologie a krevni transfuze has several departments that took part in Clinical trials: "Institute of Hematology and Blood Transfusion" - 12 trials